Drug Topics

SEPTEMBER 1, 2023

Readers, we want to hear from you!

281

281

PharmaVoice

SEPTEMBER 1, 2023

Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.

264

264

Drug Topics

SEPTEMBER 1, 2023

The FDA plans to finalize its ban on menthol tobacco products in the coming months, and the Department of Health and Human Services proposes comprehensive staffing requirements for nursing homes.

Nursing Homes 247

Nursing Homes FDA 247

PharmaVoice

SEPTEMBER 1, 2023

The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.

233

233

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

SEPTEMBER 1, 2023

A recent study found that lower vitamin k status was associated with higher rates of chronic obstructive lung disease, wheezing, and asthma.

247

247

STAT

SEPTEMBER 1, 2023

In the midst of the Covid-19 surge during the winter of 2021, the Pittsburgh-based UPMC health system received 450 doses of Evusheld — a scarce antibody cocktail being used at the time to prevent immunocompromised patients from being infected by the coronavirus. But those doses were just a fraction of a percent of what the sprawling 35-hospital system needed to protect its 200,000 immunocompromised patients.

Hospitals 143

Hospitals 143

Pharmacy Times

SEPTEMBER 1, 2023

In a previous trial, DARE-19, investigators reported that the SGLT2 inhibitor dapagliflozin did not benefit patients with COVID-19 who had cardiometabolic risk factors.

Hospitals 139

Hospitals 139

STAT

SEPTEMBER 1, 2023

The U.S. is running low on primary care physicians, with an estimated shortage of between 17,800 and 48,000 predicted by 2034. The dearth of doctors in this area has broad ramifications, ranging from more patients seeking care from specialty and emergency medicine to increased costs to the health care system  and poorer public health outcomes. One of the challenges to growing the ranks of primary care doctors is that family physicians and others in primary care typically have a much lower i

139

139

Pharmacy Times

SEPTEMBER 1, 2023

Heart health may influence long-term brain health as early as middle age.

123

123

STAT

SEPTEMBER 1, 2023

WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J&J drug called Stelara, a treatment for Crohn’s disease, was on the list. But had the therapy been approved 98 days later, it may not have made the list at all.

134

134

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

SEPTEMBER 1, 2023

Although the pandemic has negatively influenced the care that patients with cardiovascular conditions receive, the study authors found that there were not significant inequities regarding patients’ race.

121

121

STAT

SEPTEMBER 1, 2023

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured. So he’s seen the field’s highs and lows.

120

120

Fierce Pharma

SEPTEMBER 1, 2023

After months of legal wrangling, Amgen is free to go forward with its $27.8 billion buyout of Horizon Therapeutics. | Friday, the U.S. Federal Trade Commission (FTC) said it reached a proposed consent order with Amgen to address “the potential competitive harm” that could result from the merger deal. Now, Amgen is free to go forward with its $28 billion buyout.

118

118

STAT

SEPTEMBER 1, 2023

Eleven years ago, the Affordable Care Act codified a critical aspect of postpartum care: breastfeeding support. The hard part — the legislation — was done. Yet so far, no meaningful implementation and enforcement of this policy has occurred.

120

120

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Drug Store News

SEPTEMBER 1, 2023

Ginger Graham, current lead independent director, has been appointed interim CEO.

116

116

STAT

SEPTEMBER 1, 2023

After months of legal sparring, Amgen and Horizon Therapeutics settled a lawsuit with the Federal Trade Commission that will allow the company to proceed with their planned $28 billion merger. The agreement comes after the agency challenged the deal over concerns the combined company could abuse its power to entrench the monopolies for two drugs currently sold by Horizon.

Packaging 120

Packaging Insurance 120

pharmaphorum

SEPTEMBER 1, 2023

AI specialist Intelligent Omics bags J&J deal Phil.

115

115

Fierce Healthcare

SEPTEMBER 1, 2023

As more and more cell and gene therapies come to the market, these high-cost drugs are set to have a major impact on cash-strapped Medicaid programs, according to a

108

108

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

SEPTEMBER 1, 2023

Harnessing CRM to drive innovation, strong customer experiences in life sciences Mike.

111

111

The Guardian - Pharmaceutical Industry

SEPTEMBER 1, 2023

V&A has faced criticism for being slow to disassociate itself from benefactors with role in US opioid epidemic The V&A Dundee has become the latest UK museum to remove a reference to the money it received from the Sackler family amid continuing anger over its central role in the opioid epidemic in the US. The £80m museum, Scotland’s first devoted to design, opened in 2018 and had among its donors the Sackler Trust, which gave £500,000.

107

107

pharmaphorum

SEPTEMBER 1, 2023

Or Shaval, CEO of Remepy and Shahar Shelly, the company’s chief medical officer, join Editor in Chief Jonah Comstock to talk about their unorthodox approach and the science that underpins it. They discuss how their in-development products are similar and different from traditional digital therapeutics.

111

111

Drug Store News

SEPTEMBER 1, 2023

Four weeks of anniversary deals start Sept. 1 and run through Sept. 28, with new products and promotions each week, both in-store and online.

106

106

pharmaphorum

SEPTEMBER 1, 2023

Otsuka makes psychedelics play, buying Mindset Phil.

111

111

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

105

105

pharmaphorum

SEPTEMBER 1, 2023

Sanofi names VC leader Houman Ashrafian as R&D chief Phil.

105

105

Fierce Pharma

SEPTEMBER 1, 2023

After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa. | After a groundbreaking approval for Tecentriq, Roche has another positive early-stage lung cancer trial to celebrate. This time, the honor belongs to a targeted therapy in Alecensa.

105

105

Drug Store News

SEPTEMBER 1, 2023

Inspired by the realm of enchantment and mystery, the collection is the brand’s first line of shimmering and shifting magnetic nail polishes.

105

105

Pharmaceutical Technology

SEPTEMBER 1, 2023

Otsuka Pharmaceutical has signed a definitive arrangement agreement to acquire Mindset Pharma, in an all-cash deal worth C$80m ($59.1m).

105

105

Fierce Pharma

SEPTEMBER 1, 2023

Approved two summers ago for chronic kidney disease (CKD) associated with type 2 diabetes, Bayer’s Kerendia (finerenone) isn’t off to the flying start expected of a potential blockbuster. | Bayer plans three new trials to assess its potential blockbuster medicine Kerendia in heart failure. The drug was first approved 2 years ago in CKD associated with diabetes.

104

104

pharmaphorum

SEPTEMBER 1, 2023

Sage sheds staff after narrow Zurzuvae approval Phil.

102

102

STAT

SEPTEMBER 1, 2023

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Please note that our regular feature — in which we spotlight someone — will return later this month.

102

102

Fierce Healthcare

SEPTEMBER 1, 2023

Rosalind Brewer will step down as CEO of Walgreens, kicking off the search for her replacement, the pharmacy chain announced Friday morning.

98

98

BioPharm

SEPTEMBER 1, 2023

The pandemic and shifting focus to more complex therapeutics are driving growth in the outsourced formulation development services market.

98

98